These authors warned clinicians to always consider that OCS-dependent severe asthma patients could have an underlying (ANCA-negative) EGPA (with high levels of blood eosinophils masked by OCS maintenance therapy) and suggested stopping Dupilumab and (re)starting anti-IL-5 or anti-IL-5R therapies if eosinophils rise to more than 1000 cells/mcL and asthma symptoms worsen. The gene discussed is IL5; the disease is asthma.